NCT06258122 Evolution of the Clinical, Immuno-virological and Aging Trajectory of Patients Living With HIV
| NCT ID | NCT06258122 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida |
| Condition | HIV Infections |
| Study Type | OBSERVATIONAL |
| Enrollment | 120 participants |
| Start Date | 2024-04-23 |
| Primary Completion | 2024-12-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 120 participants in total. It began in 2024-04-23 with a primary completion date of 2024-12-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Main objective is: * To characterize the evolution of the immuno-virological profile of circulating blood cells and immune aging in patients who had participated to TEMPO-1 in 2007-2008 * To evaluate the role of immune aging and inflammatory profile in the occurrence of comorbidities in HIV-infected individuals over a 15-year period The alterations that affect the innate and adaptive immune cell compartments in HIV-infected patients are reminiscent of the process of immune aging, characteristic of old age. These alterations, the presumed cause of which is the chronic systemic immune activation established in patients, contribute to the depletion of lymphoid resources which probably leads to the decline of immune competence with the progression of HIV disease. The comparison between HIV-1-infected patients and uninfected older adults goes beyond the mere appearance of immunosenescence and extends to the deterioration of a number of physiological functions linked to inflammation and to systemic aging. By inducing persistent and lasting immune activation, HIV-1 infection is now considered a model of accelerated immunosenescence and systemic aging. During this process, the immune system quickly becomes exhausted, because the source of its exhaustion (i.e. HIV) cannot be eliminated. To determine which factors may contribute to immunosenescence in HIV-1 infection, we propose an extensive immune and virological evaluation in patients who participated in a cross-sectional assessment of immune functions and TEMPO-1 viral reservoirs after 15 years of evolution in order to determine their immune and viral trajectories, to compare these trajectories with the major clinical events and the comorbidities occurring in them.
Eligibility Criteria
Inclusion Criteria: * Previous participation to the TEMPO-1 study * 18 years of age or older * HIV-infected individuals and non-HIV infected control group * Be affiliated or beneficiary of a social security scheme * Have signed the consent form. Exclusion Criteria: * Subject under " sauvegarde de justice " (judicial protection due to temporarily and slightly diminished mental or physical faculties), or under legal guardianship
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06258122 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying HIV Infections. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06258122 currently recruiting?
Yes, NCT06258122 is actively recruiting participants. Contact the research team at yasmine.dudoit@aphp.fr for enrollment information.
Where is the NCT06258122 trial being conducted?
This trial is being conducted at Paris, France.
Who is sponsoring the NCT06258122 clinical trial?
NCT06258122 is sponsored by Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida. The trial plans to enroll 120 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.